The high-fat diet-fed mouse -: A model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes

被引:798
作者
Winzell, MS [1 ]
Ahrén, B [1 ]
机构
[1] Lund Univ, Dept Med, Ctr Biomed, S-22184 Lund, Sweden
关键词
D O I
10.2337/diabetes.53.suppl_3.S215
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study characterizes the high-fat diet-fed mouse as a model for impaired glucose tolerance (IGT) and type 2 diabetes. Female C57BL/6J mice were fed a high-fat diet (58% energy by fat) or a normal diet (11% fat). Body weight was higher in mice fed the high-fat diet already after the first week, due to higher dietary intake in combination with lower metabolic efficiency. Circulating glucose increased after 1 week on high-fat diet and remained elevated at a level of similar to1 mmol/l throughout the 12-month study period. In contrast, circulating insulin increased progressively by time. Intravenous glucose challenge revealed a severely compromised insulin response in association with marked glucose intolerance already after 1 week. To illustrate the usefulness of this model for the development of new treatment, mice were fed an orally active inhibitor of dipeptidyl peptidase-IV (LAF237) in the drinking water (0.3 mg/ ml) for 4 weeks. This normalized glucose tolerance, as judged by an oral glucose tolerance test, in association with augmented insulin secretion. We conclude that the high-fat diet-fed C57BL/6J mouse model is a robust model for IGT and early type 2 diabetes, which may be used for studies on pathophysiology and development of new treatment.
引用
收藏
页码:S215 / S219
页数:5
相关论文
共 25 条
[1]   Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice [J].
Ahren, B ;
Simonsson, E ;
Scheurink, AJW ;
Mulder, H ;
Myrsen, U ;
Sundler, F .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1997, 46 (01) :97-106
[2]   Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice [J].
Ahrén, B ;
Holst, JJ ;
Mårtensson, H ;
Balkan, B .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 404 (1-2) :239-245
[3]   1,5-anhydro-D-fructose increases glucose tolerance by increasing glucagon-like peptide-1 and insulin in mice [J].
Ahrén, B ;
Holst, JJ ;
Yu, SK .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 397 (01) :219-225
[4]   Marked hyperleptinemia after high-fat diet associated with severe glucose intolerance in mice [J].
Ahrén, B ;
Scheurink, AJW .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1998, 139 (04) :461-467
[5]   Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes [J].
Ahrén, B ;
Landin-Olsson, M ;
Jansson, PA ;
Svensson, M ;
Holmes, D ;
Schweizer, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2078-2084
[6]   Insufficient islet compensation to insulin resistance vs. reduced glucose effectiveness in glucose-intolerant mice [J].
Ahrén, B ;
Pacini, G .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2002, 283 (04) :E738-E744
[7]   Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse [J].
Ahren, B ;
Sundkvist, G ;
Mulder, H ;
Sundler, F .
DIABETOLOGIA, 1996, 39 (04) :383-390
[8]   Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes [J].
Ahrén, B ;
Simonsson, E ;
Larsson, H ;
Landin-Olsson, M ;
Torgeirsson, H ;
Jansson, PA ;
Sandqvist, M ;
Båvenholm, P ;
Efendic, S ;
Eriksson, JW ;
Dickinson, S ;
Holmes, D .
DIABETES CARE, 2002, 25 (05) :869-875
[9]   Increased insulin secretion and normalization of glucose tolerance by cholinergic agonism in high fat-fed mice [J].
Ahrén, B ;
Sauerberg, P ;
Thomsen, C .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1999, 277 (01) :E93-E102
[10]   Gut peptides and type 2 diabetes mellitus treatment [J].
Bo Ahrén .
Current Diabetes Reports, 2003, 3 (5) :365-372